Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
SPRO — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

3.98

Margin Of Safety %

11

Put/Call OI Ratio

0.09

EPS Next Q Diff

EPS Last/This Y

0.52

EPS This/Next Y

0.09

Price

2.84

Target Price

4

Analyst Recom

3

Performance Q

10.47

Upside

85.3%

Beta

1.46

Ticker: SPRO




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-05-18SPRO2.570.060.0116347
2026-05-19SPRO2.580.060.0016673
2026-05-20SPRO2.620.050.0017851
2026-05-21SPRO2.680.050.0018399
2026-05-22SPRO2.760.050.0018591
2026-05-26SPRO2.870.050.0018994
2026-05-27SPRO2.930.050.0019105
2026-05-28SPRO2.910.051.5219789
2026-05-29SPRO2.820.070.0020537
2026-06-02SPRO2.840.070.0021565
2026-06-03SPRO2.80.070.0121772
2026-06-04SPRO2.970.060.5922141
2026-06-05SPRO2.830.080.0122781
2026-06-08SPRO2.740.080.4623088
2026-06-09SPRO2.570.070.2823364
2026-06-10SPRO2.540.080.7724263
2026-06-11SPRO2.70.090.0424930
2026-06-12SPRO2.840.090.0724894
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-05-18SPRO2.58- - 0.67
2026-05-19SPRO2.58- - 0.67
2026-05-20SPRO2.62- - 0.67
2026-05-21SPRO2.68- - 0.67
2026-05-22SPRO2.76- - 0.67
2026-05-26SPRO2.87- - 0.67
2026-05-27SPRO2.93- - 0.67
2026-05-28SPRO2.91- - 0.67
2026-05-29SPRO2.83- - 0.67
2026-06-01SPRO2.83- - 0.67
2026-06-02SPRO2.85- - 0.67
2026-06-03SPRO2.80- - 0.67
2026-06-04SPRO2.98- - 0.67
2026-06-05SPRO2.83- - 0.67
2026-06-08SPRO2.75- - 0.67
2026-06-09SPRO2.58- - 0.67
2026-06-10SPRO2.54- - 0.67
2026-06-11SPRO2.69- - 0.67
2026-06-12SPRO2.84- - 0.67
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-05-18SPRO-1.300.982.75
2026-05-19SPRO-1.300.982.75
2026-05-20SPRO-1.300.982.75
2026-05-21SPRO-1.300.982.75
2026-05-22SPRO-1.300.982.75
2026-05-26SPRO-1.30-0.912.75
2026-05-27SPRO-1.30-0.912.75
2026-05-28SPRO-1.30-0.913.84
2026-05-29SPRO-1.30-0.913.84
2026-06-02SPRO-1.30-1.553.84
2026-06-03SPRO-1.30-1.553.84
2026-06-04SPRO-1.30-1.553.84
2026-06-05SPRO-1.30-1.553.84
2026-06-08SPRO-1.30-1.553.84
2026-06-09SPRO-1.30-1.553.84
2026-06-10SPRO-1.30-1.553.98
2026-06-11SPRO-1.30-1.553.98
2026-06-12SPRO-1.30-1.553.98
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.2

Avg. EPS Est. Next Quarter

Insider Transactions

-1.3

Institutional Transactions

-1.55

Beta

1.46

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

3.15

Quality Score

71

Growth Score

51

Sentiment Score

12

Actual DrawDown %

85.7

Max Drawdown 5-Year %

-97.1

Target Price

4

P/E

11.69

Forward P/E

3.75

PEG

P/S

3.01

P/B

3.12

P/Free Cash Flow

22.79

EPS

0.24

Average EPS Est. Cur. Y​

0.67

EPS Next Y. (Est.)

0.76

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

27.82

Relative Volume

1.08

Return on Equity vs Sector %

1.2

Return on Equity vs Industry %

17.5

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

SPRO Healthcare
$2.85
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
12/20
Pullback
4/25
Volume
4/15
Valuation
17/20
TP/AR
0/10
Options
8/10
RSI
55.7
Range 1M
61.3%
Sup Dist
11.2%
🚀
Momentum Growth
Ride accelerating trends
N/A
39 /100
WEAK
Momentum
9/25
Growth
15/30
Estimates
4/20
Inst/Vol
3/15
Options
8/10
EPS Yr
346.7%
EPS NY
13.4%
52W%
70.8%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +254.6% upside
Quality
17/30
Valuation
22/30
Growth
13/25
Stability
6/10
LT Trend
3/5
Upside
+254.6%
Quality
71
MoS
11%
Spero Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 25
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
SPRO

Latest News

Caricamento notizie per SPRO
stock quote shares SPRO – Spero Therapeutics, Inc. Stock Price stock today
news today SPRO – Spero Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SPRO – Spero Therapeutics, Inc. yahoo finance google finance
stock history SPRO – Spero Therapeutics, Inc. invest stock market
stock prices SPRO premarket after hours
ticker SPRO fair value insiders trading